JP2004524323A - 結腸直腸癌診断のためのテトラデンテートペプチド−キレートコンジュゲート - Google Patents
結腸直腸癌診断のためのテトラデンテートペプチド−キレートコンジュゲート Download PDFInfo
- Publication number
- JP2004524323A JP2004524323A JP2002569189A JP2002569189A JP2004524323A JP 2004524323 A JP2004524323 A JP 2004524323A JP 2002569189 A JP2002569189 A JP 2002569189A JP 2002569189 A JP2002569189 A JP 2002569189A JP 2004524323 A JP2004524323 A JP 2004524323A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- chelate
- conjugate
- receptor
- chelate conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013522 chelant Substances 0.000 title claims abstract description 39
- 206010009944 Colon cancer Diseases 0.000 title abstract description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 title abstract description 8
- 238000003745 diagnosis Methods 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 79
- 239000002738 chelating agent Substances 0.000 claims abstract description 34
- 239000003446 ligand Substances 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000012217 radiopharmaceutical Substances 0.000 claims abstract description 15
- 229940121896 radiopharmaceutical Drugs 0.000 claims abstract description 14
- 230000002799 radiopharmaceutical effect Effects 0.000 claims abstract description 14
- 230000002285 radioactive effect Effects 0.000 claims abstract description 10
- 150000004696 coordination complex Chemical class 0.000 claims abstract description 9
- 150000004985 diamines Chemical class 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 239000000562 conjugate Substances 0.000 claims description 49
- 238000003384 imaging method Methods 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 230000021615 conjugation Effects 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 125000005647 linker group Chemical group 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- 229960002684 aminocaproic acid Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000863 peptide conjugate Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- 125000004077 D-glutamic acid group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])=O 0.000 claims 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 19
- 229910052751 metal Inorganic materials 0.000 abstract description 10
- 239000002184 metal Substances 0.000 abstract description 10
- 210000001072 colon Anatomy 0.000 abstract description 5
- 238000002059 diagnostic imaging Methods 0.000 abstract description 5
- 230000002496 gastric effect Effects 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 4
- 231100000765 toxin Toxicity 0.000 abstract description 4
- 201000009840 acute diarrhea Diseases 0.000 abstract description 3
- 230000003211 malignant effect Effects 0.000 abstract description 3
- 101710146739 Enterotoxin Proteins 0.000 abstract description 2
- 241000588724 Escherichia coli Species 0.000 abstract description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 abstract description 2
- 102000014469 Guanylate cyclase Human genes 0.000 abstract description 2
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 2
- 230000000112 colonic effect Effects 0.000 abstract description 2
- 239000000147 enterotoxin Substances 0.000 abstract description 2
- 231100000655 enterotoxin Toxicity 0.000 abstract description 2
- 230000010309 neoplastic transformation Effects 0.000 abstract description 2
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- XKZQKPRCPNGNFR-UHFFFAOYSA-N 2-(3-hydroxyphenyl)phenol Chemical compound OC1=CC=CC(C=2C(=CC=CC=2)O)=C1 XKZQKPRCPNGNFR-UHFFFAOYSA-N 0.000 abstract 1
- 125000004427 diamine group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 49
- 102000005962 receptors Human genes 0.000 description 43
- 108020003175 receptors Proteins 0.000 description 43
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 40
- 238000004128 high performance liquid chromatography Methods 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 201000009030 Carcinoma Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 20
- 238000000034 method Methods 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 238000000163 radioactive labelling Methods 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 206010027476 Metastases Diseases 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000002372 labelling Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- -1 Bisamide dithiol compounds Chemical class 0.000 description 8
- HAYVTMHUNMMXCV-IMJSIDKUSA-N Cys-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CS HAYVTMHUNMMXCV-IMJSIDKUSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- 206010027457 Metastases to liver Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 238000007363 ring formation reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000007259 addition reaction Methods 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 150000004662 dithiols Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000003973 alkyl amines Chemical class 0.000 description 3
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000001588 bifunctional effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 150000001945 cysteines Chemical class 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052713 technetium Inorganic materials 0.000 description 3
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- YXTDAZMTQFUZHK-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O YXTDAZMTQFUZHK-ZVGUSBNCSA-L 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- LUULAWGQWYTHTP-UHFFFAOYSA-N 1-methylpyrrolidin-2-one;piperidine Chemical compound C1CCNCC1.CN1CCCC1=O LUULAWGQWYTHTP-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- CHXRIVJFJWPWMR-UHFFFAOYSA-N 2-chloro-2-methyl-3-nitrosobutane Chemical compound O=NC(C)C(C)(C)Cl CHXRIVJFJWPWMR-UHFFFAOYSA-N 0.000 description 1
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- 101001068640 Nicotiana tabacum Basic form of pathogenesis-related protein 1 Proteins 0.000 description 1
- HWZUDASOMGNLSM-UHFFFAOYSA-N O=P1OCOP(=O)O1 Chemical compound O=P1OCOP(=O)O1 HWZUDASOMGNLSM-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 235000010787 Rubus niveus Nutrition 0.000 description 1
- 244000157378 Rubus niveus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001295 alanines Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- VJLOFJZWUDZJBX-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;chloride Chemical compound [Cl-].OCC[NH2+]CCO VJLOFJZWUDZJBX-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940102859 methylene diphosphonate Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 230000003537 radioprotector Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- MIRQOHKSVLYPDX-UHFFFAOYSA-N sexipyridine Chemical compound C1=CC(C=2C=CC=C(N=2)C=2N=C(C=CC=2)C=2N=C(C=CC=2)C=2N=C(C=CC=2)C=2N=C3C=CC=2)=NC3=C1 MIRQOHKSVLYPDX-UHFFFAOYSA-N 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229910001432 tin ion Inorganic materials 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000006478 transmetalation reaction Methods 0.000 description 1
- BYGOPQKDHGXNCD-UHFFFAOYSA-N tripotassium;iron(3+);hexacyanide Chemical compound [K+].[K+].[K+].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] BYGOPQKDHGXNCD-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0105224.0A GB0105224D0 (en) | 2001-03-02 | 2001-03-02 | Improved peptide-chelate conjugates |
| PCT/GB2002/000857 WO2002070018A2 (en) | 2001-03-02 | 2002-03-01 | Tetradentate peptide-chelate conjugates for colorectal cancer diagnosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004524323A true JP2004524323A (ja) | 2004-08-12 |
| JP2004524323A5 JP2004524323A5 (enExample) | 2005-12-22 |
Family
ID=9909880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569189A Pending JP2004524323A (ja) | 2001-03-02 | 2002-03-01 | 結腸直腸癌診断のためのテトラデンテートペプチド−キレートコンジュゲート |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7608242B2 (enExample) |
| EP (1) | EP1368064B1 (enExample) |
| JP (1) | JP2004524323A (enExample) |
| AT (1) | ATE556722T1 (enExample) |
| CA (1) | CA2439579A1 (enExample) |
| ES (1) | ES2385028T3 (enExample) |
| GB (1) | GB0105224D0 (enExample) |
| WO (1) | WO2002070018A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017503763A (ja) * | 2013-12-03 | 2017-02-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｃｃ発現細胞を撮像するための化合物及び組成物 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0224799D0 (en) * | 2002-10-25 | 2002-12-04 | Amersham Plc | Improved complex compositions |
| NO20030115D0 (no) | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
| EP1599165A4 (en) * | 2003-02-10 | 2010-09-08 | Univ Jefferson | THE USE OF GCC LIGANDS |
| US7842280B2 (en) * | 2006-09-06 | 2010-11-30 | Case Western Reserve University | Flexibly labeling peptides |
| WO2009108868A2 (en) * | 2008-02-27 | 2009-09-03 | Radiomedix Inc. | Radiolabeled hedgehog derivatives for imaging and therapy |
| WO2010027473A2 (en) * | 2008-09-03 | 2010-03-11 | Board Of Trustees Of Michigan State University | Immunogenic escherichia coli heat stable enterotoxin |
| CN102822194B (zh) * | 2009-12-07 | 2016-10-26 | 硬木药品公司 | 用于胃肠病症的治疗 |
| GB201016206D0 (en) * | 2010-09-27 | 2010-11-10 | Ge Healthcare Ltd | Apoptosis imaging agents |
| GB201103696D0 (en) | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
| US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| WO2012170766A1 (en) | 2011-06-08 | 2012-12-13 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
| GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
| GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4545931A (en) | 1983-01-03 | 1985-10-08 | Scripps Clinic And Research Foundation | Synthetic heat-stable enterotoxin polypeptide of Escherichia coli |
| US4886663A (en) | 1983-01-03 | 1989-12-12 | Scripps Clinic And Research Foundation | Synthetic heat-stable enterotoxin polypeptide of Escherichia coli and multimers thereof |
| US5242679A (en) * | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| US5849261A (en) | 1991-02-08 | 1998-12-15 | Diatide, Inc. | Radiolabeled vasoactive intestinal peptides for diagnosis and therapy |
| WO1994008949A2 (en) * | 1992-10-08 | 1994-04-28 | Amersham International Plc | Metal-oxime chelates for use as radiopharmaceutical agents |
| CA2167281C (en) | 1993-07-15 | 2001-09-04 | Richard T. Dean | Radiolabeled somatostatin-derived peptides for imaging and therapeutic uses |
| AU7261994A (en) * | 1993-07-19 | 1995-02-20 | Resolution Pharmaceuticals Inc. | Hydrazino-type radionuclide chelators having an n3s configuration |
| JP4194113B2 (ja) | 1993-10-26 | 2008-12-10 | トーマス・ジェファーソン・ユニバーシティ | 結腸直腸癌細胞に特異的に結合する組成物およびその使用方法 |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| DE19536781A1 (de) | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope |
| AU9452198A (en) * | 1997-10-15 | 1999-05-17 | Nycomed Imaging As | Complexing agents and targeting immunoreagents |
| WO1999039748A1 (en) | 1998-02-06 | 1999-08-12 | Nycomed Imaging As | Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods |
-
2001
- 2001-03-02 GB GBGB0105224.0A patent/GB0105224D0/en not_active Ceased
-
2002
- 2002-03-01 AT AT02701431T patent/ATE556722T1/de active
- 2002-03-01 CA CA002439579A patent/CA2439579A1/en not_active Abandoned
- 2002-03-01 US US10/469,801 patent/US7608242B2/en not_active Expired - Fee Related
- 2002-03-01 WO PCT/GB2002/000857 patent/WO2002070018A2/en not_active Ceased
- 2002-03-01 JP JP2002569189A patent/JP2004524323A/ja active Pending
- 2002-03-01 ES ES02701431T patent/ES2385028T3/es not_active Expired - Lifetime
- 2002-03-01 EP EP02701431A patent/EP1368064B1/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017503763A (ja) * | 2013-12-03 | 2017-02-02 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｃｃ発現細胞を撮像するための化合物及び組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060222593A1 (en) | 2006-10-05 |
| GB0105224D0 (en) | 2001-04-18 |
| WO2002070018A3 (en) | 2002-12-05 |
| ES2385028T3 (es) | 2012-07-17 |
| CA2439579A1 (en) | 2002-09-12 |
| US7608242B2 (en) | 2009-10-27 |
| EP1368064A2 (en) | 2003-12-10 |
| ATE556722T1 (de) | 2012-05-15 |
| EP1368064B1 (en) | 2012-05-09 |
| WO2002070018A2 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7534498B2 (ja) | Ｇｒｐｒ陽性ガンの検出、診断及び治療のためのｇｒｐｒアンタゴニスト | |
| AU2019407851B2 (en) | Dual mode 18f-labelled theranostic compounds and uses thereof | |
| JP5784911B2 (ja) | ボンベシンアナログペプチドアンタゴニスト複合体 | |
| JP3753734B2 (ja) | ペプチド誘導の放射性核種キレート化剤 | |
| JP3647881B2 (ja) | 放射性金属元素結合ペプチドの類似化合物 | |
| US7147838B2 (en) | Gastrin receptor-avid peptide conjugates | |
| US5830431A (en) | Radiolabeled peptide compositions for site-specific targeting | |
| Failla et al. | Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling | |
| AU728712B2 (en) | Method for the detection and localization of malignant human tumours | |
| KR20130132935A (ko) | Ｎｏｔａ에 의해 복합체를 형성한 알루미늄―〔１８〕플루오라이드로 표지된 ｈｅｒ２ 결합 펩티드 | |
| AU2016333334A1 (en) | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer | |
| WO1998047524A9 (en) | Gastrin receptor-avid peptide conjugates | |
| KR20030061811A (ko) | 펩티드-기재 화합물 | |
| US7608242B2 (en) | Peptide-chelate conjugates | |
| AU2020257786B2 (en) | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer | |
| JP7541532B2 (ja) | 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物 | |
| US7060247B2 (en) | Gastrin receptor-avid peptide conjugates | |
| JP2022017480A (ja) | 診断及び治療のための、改善された薬物動態及びコレシストキニン－２受容体（ｃｃｋ２ｒ）への標的化 | |
| KR20130132939A (ko) | １８ｆ - 함유 유기실리콘 화합물로 표지된 ｈｅｒ２ 결합 펩티드 | |
| AU2003239351A1 (en) | Radiopharmaceutical formulations | |
| KR20220152322A (ko) | 생체내 알파-v-베타-6-인테그린 접근을 위한 환형 펩타이드 및 그의 컨쥬게이트 | |
| JP7787083B2 (ja) | アルファ－ｖ－ベータ－６－インテグリンをインビボでアドレッシングするための環状ペプチド及びそれらのコンジュゲート | |
| AU2002234761A1 (en) | Tetradentate peptide-chelate conjugates for colorectal cancer diagnosis | |
| KR20250011145A (ko) | 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드 | |
| TW202540073A (zh) | 靶向ｓｓｔｒ受體的放射性化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20041124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041217 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20041217 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080401 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080701 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080708 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080731 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080807 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080901 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080908 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081125 |